CYDY
CytoDyn Inc.
Price Chart
Latest Quote
$0.27
-0.01 (-3.93%)
Current Price
| Previous Close | $0.28 |
| Open | $0.27 |
| Day High | $0.28 |
| Day Low | $0.27 |
| Volume | 600,856 |
Stock Information
| Shares Outstanding | 1.37B |
| Total Debt | $28.82M |
| Cash Equivalents | $15.65M |
| Net Income | $-40.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $368.46M |
| EPS (TTM) | $-0.04 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $395.08M |
| Income | $-40.28M |
| Book/sh | $-0.08 |
| Cash/sh | $0.01 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 0.31 |
| Current Ratio | 0.37 |
Returns & Margins
| ROA | -67.45% |
Ownership
| Insider Ownership | 0.01% |
| Institutional Ownership | 0.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.49 |
| P/B | -3.49 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.30 |
| SMA50 | $0.32 |
| SMA200 | $0.28 |
| RSI | 28.17 |
| ATR | 0.0208 |
| Shares Float | 1.37B |
| Volatility | 1.12 |
| Rel Volume | 0.35 |
Performance History
| Week | -7.24% |
| Month | -23.14% |
| Quarter | -3.93% |
| 6 Months | -15.94% |
| YTD | -0.37% |
| Year | -20.88% |
| 3 Years | +3.46% |
| 5 Years | -85.84% |
| 10 Years | -79.15% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.27 | 600,856 |
| 2026-06-17 | $0.27 | 1,964,000 |
| 2026-06-16 | $0.28 | 1,209,000 |
| 2026-06-15 | $0.28 | 2,798,900 |
| 2026-06-12 | $0.29 | 1,251,600 |
| 2026-06-11 | $0.29 | 1,288,400 |
| 2026-06-10 | $0.29 | 1,202,500 |
| 2026-06-09 | $0.30 | 1,115,900 |
| 2026-06-08 | $0.30 | 1,230,800 |
| 2026-06-05 | $0.29 | 1,513,600 |
| 2026-06-04 | $0.29 | 741,200 |
| 2026-06-03 | $0.28 | 2,499,600 |
| 2026-06-02 | $0.29 | 848,000 |
| 2026-06-01 | $0.30 | 2,174,600 |
| 2026-05-29 | $0.30 | 1,787,200 |
| 2026-05-28 | $0.30 | 3,162,000 |
| 2026-05-27 | $0.32 | 2,460,500 |
| 2026-05-26 | $0.34 | 2,683,900 |
| 2026-05-22 | $0.34 | 2,105,900 |
| 2026-05-21 | $0.35 | 1,377,300 |
| 2026-05-20 | $0.35 | 1,814,900 |
| 2026-05-19 | $0.35 | 1,675,100 |
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $266,000 |
| Operating Revenue | $0 | $0 | $0 | $266,000 |
| Reconciled Cost Of Revenue | - | $0 | $20,633,000 | $53,000 |
| Cost Of Revenue | - | $0 | $20,633,000 | $53,000 |
| Expenses | ||||
| Interest Expense | $4,831,000 | $5,735,000 | $6,750,000 | $15,066,000 |
| Total Expenses | $-9,661,000 | $18,058,000 | $40,576,000 | $145,670,000 |
| Other Income Expense | $-445,000 | $-13,610,000 | $-8,750,000 | $-3,853,000 |
| Net Non Operating Interest Income Expense | $-5,471,000 | $-18,173,000 | $-30,498,000 | $-61,563,000 |
| Total Other Finance Cost | $1,205,000 | $12,655,000 | $23,748,000 | $46,497,000 |
| Interest Expense Non Operating | $4,831,000 | $5,735,000 | $6,750,000 | $15,066,000 |
| Operating Expense | $-9,661,000 | $18,058,000 | $19,943,000 | $145,617,000 |
| General And Administrative Expense | $7,260,000 | $10,818,000 | $17,136,000 | $44,303,000 |
| Other Operating Expenses | - | - | $20,633,000 | $73,490,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Net Interest Income | $-5,471,000 | $-18,173,000 | $-30,498,000 | $-61,563,000 |
| Interest Income | $565,000 | $217,000 | - | - |
| Normalized Income | $4,190,000 | $-36,231,000 | $-71,074,000 | $-206,967,000 |
| Net Income From Continuing And Discontinued Operation | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Total Operating Income As Reported | $-9,661,000 | $-18,058,000 | $-40,576,000 | $-145,404,000 |
| Net Income Common Stockholders | $2,261,000 | $-51,324,000 | $-86,736,000 | $-212,448,000 |
| Net Income | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Net Income Including Noncontrolling Interests | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Net Income Continuous Operations | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Pretax Income | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Special Income Charges | $407,000 | $-13,374,000 | $0 | $-3,853,000 |
| Interest Income Non Operating | $565,000 | $217,000 | - | - |
| Operating Income | $9,661,000 | $-18,058,000 | $-40,576,000 | $-145,404,000 |
| Depreciation Amortization Depletion Income Statement | - | $29,000 | $175,000 | $781,000 |
| Depreciation And Amortization In Income Statement | - | $29,000 | $175,000 | $781,000 |
| Amortization Of Intangibles Income Statement | - | $0 | $132,000 | - |
| Depreciation Income Statement | - | $29,000 | $43,000 | - |
| Gross Profit | - | $0 | $-20,633,000 | $213,000 |
| Per Share | ||||
| Diluted EPS | $0.00 | $-0.05 | $-0.10 | $-0.31 |
| Basic EPS | $0.00 | $-0.05 | $-0.10 | $-0.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $9,039,000 | $-30,467,000 | $-64,149,000 | $-191,120,000 |
| Total Unusual Items | $-445,000 | $-13,610,000 | $-8,750,000 | $-3,853,000 |
| Total Unusual Items Excluding Goodwill | $-445,000 | $-13,610,000 | $-8,750,000 | $-3,853,000 |
| Reconciled Depreciation | $18,000 | $29,000 | $175,000 | $781,000 |
| EBITDA (Bullshit earnings) | $8,594,000 | $-44,077,000 | $-72,899,000 | $-194,973,000 |
| EBIT | $8,576,000 | $-44,106,000 | $-73,074,000 | $-195,754,000 |
| Diluted Average Shares | $1,242,922,000 | $969,509,000 | $836,528,000 | $676,900,000 |
| Basic Average Shares | $1,205,755,000 | $969,509,000 | $836,528,000 | $676,900,000 |
| Diluted NI Availto Com Stockholders | $2,261,000 | $-51,324,000 | $-86,736,000 | $-212,448,000 |
| Preferred Stock Dividends | $1,483,000 | $1,483,000 | $1,495,000 | $1,628,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Restructuring And Mergern Acquisition | $-407,000 | $0 | - | - |
| Gain On Sale Of Security | $-852,000 | $-236,000 | $-8,750,000 | - |
| Research And Development | $-16,921,000 | $7,240,000 | $2,632,000 | $27,043,000 |
| Selling General And Administration | $7,260,000 | $10,818,000 | $17,136,000 | $44,303,000 |
| Other Gand A | $3,641,000 | $4,046,000 | $6,401,000 | $27,192,000 |
| Insurance And Claims | $1,239,000 | $1,850,000 | $2,399,000 | $4,512,000 |
| Salaries And Wages | $2,380,000 | $4,922,000 | $8,336,000 | $12,599,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $5,417,000 | $0 |
| Other Special Charges | - | $13,374,000 | - | $3,853,000 |
| Amortization | - | $0 | $132,000 | - |
| Write Off | - | - | - | $73,490,000 |
| Impairment Of Capital Assets | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-96,042,000 | $-116,758,000 | $-109,501,000 | $-94,530,000 |
| Total Assets | $18,047,000 | $11,136,000 | $11,292,000 | $29,185,000 |
| Total Non Current Assets | $169,000 | $321,000 | $487,000 | $18,802,000 |
| Other Non Current Assets | $169,000 | $321,000 | $487,000 | $18,670,000 |
| Current Assets | $17,878,000 | $10,815,000 | $10,805,000 | $10,515,000 |
| Restricted Cash | $0 | $6,704,000 | $6,507,000 | $0 |
| Prepaid Assets | $3,975,000 | $1,001,000 | $1,757,000 | $6,284,000 |
| Receivables | $2,000,000 | $0 | - | - |
| Other Receivables | $2,000,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $11,903,000 | $3,110,000 | $2,541,000 | $4,231,000 |
| Cash And Cash Equivalents | $11,903,000 | $3,110,000 | $2,541,000 | $4,231,000 |
| Cash Financial | $11,903,000 | $3,110,000 | $2,541,000 | $4,231,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $132,000 |
| Other Intangible Assets | - | - | - | $132,000 |
| Inventory | - | - | - | $17,929,000 |
| Debt | ||||
| Net Debt | $15,297,000 | $26,683,000 | $32,590,000 | $32,010,000 |
| Total Debt | $27,341,000 | $30,076,000 | $35,553,000 | $36,797,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $141,000 | $997,000 | $422,000 |
| Current Debt And Capital Lease Obligation | $27,341,000 | $29,935,000 | $34,556,000 | $36,375,000 |
| Current Debt | $27,200,000 | $29,793,000 | $34,417,000 | $36,241,000 |
| Other Current Borrowings | $27,200,000 | $29,793,000 | $34,417,000 | $36,241,000 |
| Long Term Debt | - | - | $714,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $114,089,000 | $127,894,000 | $120,793,000 | $123,583,000 |
| Total Non Current Liabilities Net Minority Interest | $43,571,000 | $43,712,000 | $997,000 | $422,000 |
| Other Non Current Liabilities | $43,571,000 | $43,571,000 | - | - |
| Current Liabilities | $70,518,000 | $84,182,000 | $119,796,000 | $123,161,000 |
| Other Current Liabilities | $145,000 | $25,000 | $79,000 | $64,000 |
| Payables And Accrued Expenses | $42,754,000 | $54,014,000 | $84,826,000 | $85,200,000 |
| Interest Payable | $18,151,000 | $15,227,000 | $10,598,000 | $5,974,000 |
| Payables | $22,961,000 | $36,352,000 | $68,033,000 | $71,951,000 |
| Dividends Payable | $8,269,000 | $6,791,000 | $5,308,000 | $3,977,000 |
| Accounts Payable | $14,692,000 | $29,561,000 | $62,725,000 | $67,974,000 |
| Other Payable | - | - | $139,000 | $134,000 |
| Equity | ||||
| Common Stock Equity | $-96,042,000 | $-116,758,000 | $-109,501,000 | $-94,398,000 |
| Total Equity Gross Minority Interest | $-96,042,000 | $-116,758,000 | $-109,501,000 | $-94,398,000 |
| Stockholders Equity | $-96,042,000 | $-116,758,000 | $-109,501,000 | $-94,398,000 |
| Retained Earnings | $-887,786,000 | $-891,531,000 | $-841,690,000 | $-766,131,000 |
| Other | ||||
| Treasury Shares Number | $286,000 | $443,000 | $443,000 | $443,000 |
| Ordinary Shares Number | $1,249,174,000 | $1,058,559,000 | $918,610,000 | $719,585,000 |
| Share Issued | $1,249,460,000 | $1,059,002,000 | $919,053,000 | $720,028,000 |
| Tangible Book Value | $-96,042,000 | $-116,758,000 | $-109,501,000 | $-94,530,000 |
| Invested Capital | $-68,842,000 | $-86,965,000 | $-74,370,000 | $-58,157,000 |
| Working Capital | $-52,640,000 | $-73,367,000 | $-108,991,000 | $-112,646,000 |
| Capital Lease Obligations | $141,000 | $283,000 | $422,000 | $556,000 |
| Total Capitalization | $-96,042,000 | $-116,758,000 | $-108,787,000 | $-94,398,000 |
| Treasury Stock | $0 | $0 | $0 | $0 |
| Additional Paid In Capital | $790,495,000 | $773,714,000 | $731,270,000 | $671,013,000 |
| Capital Stock | $1,249,000 | $1,059,000 | $919,000 | $720,000 |
| Common Stock | $1,249,000 | $1,059,000 | $919,000 | $720,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $141,000 | $283,000 | $422,000 |
| Current Capital Lease Obligation | $141,000 | $142,000 | $139,000 | $134,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $278,000 | $208,000 | $335,000 | $1,522,000 |
| Current Accrued Expenses | $19,793,000 | $17,662,000 | $16,793,000 | $13,249,000 |
| Net PPE | - | - | - | $609,000 |
| Gross PPE | - | - | - | $609,000 |
| Other Properties | - | - | - | $609,000 |
| Work In Process | - | - | - | $1,665,000 |
| Raw Materials | - | - | - | $16,264,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,765,000 | $-10,982,000 | $-25,110,000 | $-77,723,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,765,000 | $-10,982,000 | $-25,110,000 | $-77,723,000 |
| Cash Flow From Continuing Operating Activities | $-8,765,000 | $-10,982,000 | $-25,110,000 | $-77,723,000 |
| Operating Gains Losses | $2,032,000 | $20,290,000 | $14,068,000 | $37,381,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | - | - | - | $0 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $9,137,000 | $25,786,000 | $41,195,000 |
| Financing Cash Flow | $10,854,000 | $11,748,000 | $29,927,000 | $48,011,000 |
| Cash Flow From Continuing Financing Activities | $10,854,000 | $11,748,000 | $29,927,000 | $48,011,000 |
| Net Common Stock Issuance | $0 | $9,137,000 | $25,786,000 | $41,195,000 |
| Common Stock Issuance | $0 | $9,137,000 | $25,786,000 | $41,195,000 |
| Net Other Financing Charges | - | $300,000 | - | - |
| Cash Dividends Paid | - | - | - | $0 |
| Preferred Stock Dividend Paid | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-710,000 | $0 | - | $0 |
| Issuance Of Debt | $0 | $2,011,000 | $895,000 | $0 |
| Interest Paid Supplemental Data | $25,000 | $45,000 | $19,000 | $63,000 |
| End Cash Position | $11,903,000 | $9,814,000 | $9,048,000 | $4,231,000 |
| Beginning Cash Position | $9,814,000 | $9,048,000 | $4,231,000 | $33,943,000 |
| Changes In Cash | $2,089,000 | $766,000 | $4,817,000 | $-29,712,000 |
| Proceeds From Stock Option Exercised | $11,564,000 | $300,000 | $3,246,000 | $6,816,000 |
| Net Issuance Payments Of Debt | $-710,000 | $2,011,000 | $895,000 | $0 |
| Net Short Term Debt Issuance | $-710,000 | $2,011,000 | $895,000 | - |
| Short Term Debt Payments | $-710,000 | $0 | - | - |
| Short Term Debt Issuance | $0 | $2,011,000 | $895,000 | - |
| Change In Working Capital | $-16,172,000 | $11,658,000 | $-1,195,000 | $-4,778,000 |
| Change In Payables And Accrued Expense | $-11,332,000 | $10,765,000 | $-3,097,000 | $-2,713,000 |
| Change In Prepaid Assets | $-4,840,000 | $893,000 | $1,902,000 | $-4,125,000 |
| Stock Based Compensation | $1,612,000 | $2,415,000 | $4,275,000 | $6,239,000 |
| Depreciation Amortization Depletion | $18,000 | $29,000 | $175,000 | $781,000 |
| Depreciation And Amortization | $18,000 | $29,000 | $175,000 | $781,000 |
| Depreciation | $18,000 | $29,000 | $43,000 | - |
| Gain Loss On Investment Securities | $852,000 | $236,000 | $8,756,000 | - |
| Net Foreign Currency Exchange Gain Loss | $1,180,000 | $6,680,000 | $5,312,000 | $37,381,000 |
| Net Income From Continuing Operations | $3,745,000 | $-49,841,000 | $-79,824,000 | $-210,820,000 |
| Other Non Cash Items | - | $4,467,000 | $37,391,000 | $19,984,000 |
| Amortization Cash Flow | - | $0 | $132,000 | - |
| Amortization Of Intangibles | - | $0 | $132,000 | - |
| Change In Inventory | - | - | $0 | $2,060,000 |
| Asset Impairment Charge | - | - | $20,633,000 | $73,490,000 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Change In Receivables | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-02-02